Pentapeptide-3 (INCI name), Pentapeptide-3V, H-Gly-Pro-Arg-Pro-Ala-NH2
A synthetic five-amino-acid peptide (Gly-Pro-Arg-Pro-Ala) that its maker designed to act like waglerin-1, a viper-venom toxin, by blocking the muscle receptor for acetylcholine, the nerve signal that makes muscles contract. It’s marketed to soften expression lines.
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
Trial: tested in people, with the result. Animal: cell or animal studies only. No study: nothing published supports it.
Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
Vialox is designed to block the nicotinic acetylcholine receptor on muscle, the switch a nerve signal flips to make a muscle contract, competing with acetylcholine as curare and the viper toxin waglerin-1 do. In its maker’s lab test, contractions of muscle cells fell 71% within a minute. Independent work is limited to computer modeling and cell tests, and no study shows it crosses skin or reaches facial muscle.
AnimalMainly from cell and animal studies; not shown in people.
Whether any reaches facial muscle through skin, and whether the maker’s wrinkle results reflect muscle effects, surface effects or chance, is unknown; the test’s design has never been published.
Supplier data
Maker’s test: cream with 5% Vialox for 28 days; the peptide content and the number of people weren’t published.
Continuous, shown over 26 weeks
The ways Vialox is most often run, each tagged with where it comes from.
Wrinkle size down by up to 49% and roughness by up to 47%; “up to” suggests best single results. The number of people and any control group weren’t published.
Sold as pure powder and in ready-made serums, often alongside Argireline or Syn-Ake. No maker or community use level could be confirmed.
Applied over expression lines, such as the forehead and around the eyes. Topical only; never inject it.
Nothing special. Skip it and use the next application as usual.
In the maker’s lab test, muscle-cell contractions fell 71% within a minute of adding it; no study shows the same happens in facial muscle through skin.
AnimalMaker’s test: wrinkle size down by up to 49% and roughness by up to 47%. Supplier data only, with no published details on who was tested.
TrialSkin irritation or redness
Patch-test first. Stop if it doesn’t settle.
No side effects reported in the maker’s 28-day test, whose size isn’t published
No independent safety data exist, so rare reactions can’t be ruled out.
Eye irritation
Keep it out of the eyes. Rinse with water if it gets in.
Stop and see a doctor for a spreading rash, swelling, blistering or hives, eye pain after contact, or any new muscle weakness.
There are almost no human safety data for Vialox, so most of these can’t be answered either way.
No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
No product label covers Vialox, so these come from human studies and from precautions based on how it works. Most important first.
Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
Precaution: not studied, so the caution follows from how it works or from a related drug. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
From the same maker and aimed at the same muscle receptor; often sold together, but the pair has never been tested.
Paired in serums as a peptide acting earlier in the nerve signal; no study has tested the combination.
No published human studies of Vialox turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
No ongoing trial of Vialox is registered, and none has finished recently without publishing its results. Checked on ClinicalTrials.gov, October 7, 2026. Every compound: trials under way.
Vialox has no published human study. The only skin figures are its maker’s 28-day results, repeated in patents and reviews without the number of people or a control group, and a 2026 review rated them at high risk of bias. Its muscle-relaxing action comes from the maker’s cell test, and skin absorption, long-term use and injection are untested.
Vialox is used on the skin, so the math is a dilution, not a syringe dose.
| Powder | Serum volume | Strength | Percent | ppm |
|---|---|---|---|---|
| 10 mg | 100 mL | 0.1 mg/mL | 0.01% | 100 ppm |
| 10 mg | 200 mL | 0.05 mg/mL | 0.005% | 50 ppm |
| 10 mg | 500 mL | 0.02 mg/mL | 0.002% | 20 ppm |
| 10 mg | 1,000 mL | 0.01 mg/mL | 0.001% | 10 ppm |
No published use level exists for the pure peptide, and the maker’s “5% Vialox” figure doesn’t state peptide content. For scale, 10 mg in 200 mL of serum gives 50 ppm; finished products with the related wrinkle peptides on this site hold about 15–120 ppm.
Every compound side by side: the half-life chart and the storage chart.
Every compound’s numbers: the identifiers table.
Sold as pure powder, often as an acetate salt, and as ready-made solutions. No published use level exists, and the maker’s “5% Vialox” test figure doesn’t state peptide content, so product strengths can’t be compared.
A synthetic five-amino-acid peptide (Gly-Pro-Arg-Pro-Ala) that its maker designed to act like waglerin-1, a viper-venom toxin, by blocking the muscle receptor for acetylcholine, the nerve signal that makes muscles contract. It’s marketed to soften expression lines.
Vialox is designed to block the nicotinic acetylcholine receptor on muscle, the switch a nerve signal flips to make a muscle contract, competing with acetylcholine as curare and the viper toxin waglerin-1 do. In its maker’s lab test, contractions of muscle cells fell 71% within a minute. Independent work is limited to computer modeling and cell tests, and no study shows it crosses skin or reaches facial muscle. Whether any reaches facial muscle through skin, and whether the maker’s wrinkle results reflect muscle effects, surface effects or chance, is unknown; the test’s design has never been published.
Not approved as a drug in the US or EU; used as a cosmetic ingredient. Cosmetics don’t need FDA approval before sale. Never nominated for FDA’s compounding bulk lists; it isn’t on any of FDA’s 503A or 503B category lists (May 2026 and March 2025 versions).
From human studies (Supplier data): Maker’s test: cream with 5% Vialox for 28 days; the peptide content and the number of people weren’t published. These are the amounts sources reference, not recommendations.
No product label covers Vialox, so these come from human studies and from precautions based on how it works. Anyone thinking of injecting it: It is a cosmetic ingredient, not made to injectable standards, and has never been tested by injection. It isn’t botulinum toxin or snake venom. People with myasthenia gravis or similar conditions: It is designed to block the muscle acetylcholine receptor, the signal impaired in myasthenia gravis. Skin absorption hasn’t been measured, and use in these conditions hasn’t been studied. Anyone mixing pure powder at high strength: No use level has been published for the pure peptide, so strong mixes are untested for benefit or safety. The “Who should avoid it” section lists 1 more group.
Before mixing: Freezer (about −20 °C), dry and away from light. After mixing: Finished serum: cool and dark, within the product’s stated shelf life. This is common practice; no product label covers it.
No. Not named on the 2026 list. It’s a topical cosmetic ingredient, not a drug of the kind S0 covers. The 2027 list adds peptides to S0’s examples but names no cosmetic ingredients.
No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
No study No published human studies. The maker reports a 28-day cream test without saying how many people took part.
No study Sold for creams and serums, but no study has measured how much passes through skin, and no published human study has tested any form. Injection is untested.
No study There’s no label and no overdose data, and no published human study exists. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
For the protocol details
For how it works, who should avoid it and the limits of the evidence
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US